Genomics and intellectual property rights

Drug Discovery Today

Volumn 4, Issue 3, 1999, Pages 134-138

  Thomas, Sandy M ^a  

^a UK Human Genetics Commission   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DNA SEQUENCE; DRUG INDUSTRY; GENETIC ANALYSIS; MEDICAL GENETICS; PATENT; PHARMACOGENETICS; REVIEW;

EID: 0033102571     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(99)01311-2     Document Type: Review

References (12)

1. Dworkin G. Philos. Trans. R. Soc. London Ser. B. 352:1997;1077-1086.
2. Thomas S.M.et al. Nature. 380:1996;387-388.
3. Heller M.A., Eisenberg R.S. Science. 280:1998;698-700.
4. Tetwilliger J.D., Weiss K.M. Curr. Opin. Biotechnol. 9:1998;578-594.
5. Thomas, S.M. et al. (1998) The Industrial Use of Genome Resources in Europe, report for the European Commission, Science and Technology Policy Research, University of Sussex, UK.
6. Goffeau A. Science. 274:1996;564-567.
7. Oliver, S. (1997) Genomics: Commercial Opportunities from a Scientific Revolution, 30 June-2 July, University of Cambridge, UK.
8. Thomas, S.M. (1997) European Collaboration in Biotechnology: the Molecular Analysis of Genomes, end of award report to the Economic and Social Science Research Council, SPRU, University of Sussex.
9. Thomas S.M.et al. Nature. 388:1997;709.
10. BioIndustry Association/Department of Trade & Industry (1998) Functional Genomics: Recent Developments from the Biotechnology Industry on the West Coast of the USA, report by ITS Mission, February, BIA/DTI, UK.
11. Thomas S.M. Expert Opinion on Therapeutic Patents. 8:1998;1401-1403.
12. Reichhardt T. Nature. 396:1998;499.